Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTVNASDAQ:AVTENYSE:CVMNASDAQ:IVVD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$2.86-4.7%$4.48$2.78▼$17.31$69.68MN/A112,690 shs62,838 shsAVTEAerovate Therapeutics$2.52+0.4%$2.49$1.25▼$30.29$73.04M1.01571,212 shs50,500 shsCVMCEL-SCI$0.21-4.1%$0.34$0.20▼$2.39$16.86M0.67937,574 shs1.07 million shsIVVDInvivyd$0.58+7.2%$1.01$0.35▼$4.03$69.47M0.094.22 million shs1.04 million shs10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-4.67%-21.43%-27.04%-71.31%+285,999,900.00%AVTEAerovate Therapeutics+0.40%+0.40%+5.00%-5.97%-91.48%CVMCEL-SCI-4.15%-12.33%-34.45%-49.29%-88.15%IVVDInvivyd+7.24%-5.91%-38.35%+20.65%-84.80%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAVTEAerovate Therapeutics0.7794 of 5 stars1.01.00.00.02.91.71.3CVMCEL-SCIN/AN/AN/AN/AN/AN/AN/AN/AIVVDInvivyd3.3524 of 5 stars3.64.00.00.01.92.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$20.40613.29% UpsideAVTEAerovate Therapeutics 2.00Hold$2.25-10.71% DownsideCVMCEL-SCI 0.00N/AN/AN/AIVVDInvivyd 3.20Buy$7.891,262.03% UpsideCurrent Analyst Ratings BreakdownLatest CVM, ARTV, AVTE, and IVVD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025ARTVArtiva BiotherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$23.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.00 ➝ $18.003/25/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/20/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/5/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.002/24/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/24/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.002/4/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/3/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$251K277.60N/AN/AN/A∞AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AIVVDInvivyd$25.38M2.74N/AN/A$1.61 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva BiotherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/AAVTEAerovate Therapeutics-$75.52M-$2.44N/AN/AN/AN/A-90.19%-77.47%5/12/2025 (Estimated)CVMCEL-SCI-$26.92M-$0.48N/AN/AN/AN/A-238.05%-104.65%N/AIVVDInvivyd-$198.64M-$1.44N/A5.26N/AN/A-155.33%-114.88%5/8/2025 (Estimated)Latest CVM, ARTV, AVTE, and IVVD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024AVTEAerovate Therapeutics-$0.19-$0.19N/A-$0.19N/AN/A3/20/2025Q4 2024IVVDInvivyd-$0.25-$0.15+$0.10-$0.15$13.57 million$13.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A11.3311.33AVTEAerovate TherapeuticsN/A8.788.78CVMCEL-SCI0.661.071.09IVVDInvivydN/A1.921.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AAVTEAerovate TherapeuticsN/ACVMCEL-SCI12.08%IVVDInvivyd70.36%Insider OwnershipCompanyInsider OwnershipARTVArtiva BiotherapeuticsN/AAVTEAerovate Therapeutics24.90%CVMCEL-SCI16.24%IVVDInvivyd17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.36 millionN/AN/AAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCVMCEL-SCI4380.11 million64.67 millionOptionableIVVDInvivyd100119.96 million98.21 millionOptionableCVM, ARTV, AVTE, and IVVD HeadlinesRecent News About These CompaniesInvivyd, Inc. (NASDAQ:IVVD) Sees Large Decline in Short InterestMarch 31 at 2:41 PM | marketbeat.comInvivyd adds venture capitalist Ajay Royan to boardMarch 29, 2025 | uk.investing.comInvivyd (NASDAQ:IVVD) Earns Buy Rating from HC WainwrightMarch 28, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)March 27, 2025 | marketbeat.comInvivyd Appoints Ajay Royan to Board of DirectorsMarch 26, 2025 | tipranks.comInvivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of DirectorsMarch 26, 2025 | globenewswire.comInvivyd's (IVVD) "Buy" Rating Reiterated at D. Boral CapitalMarch 21, 2025 | marketbeat.comInvivyd reports FY24 EPS ($1.43) vs. ($1.81) last yearMarch 21, 2025 | markets.businessinsider.comInvivyd (NASDAQ:IVVD) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPSMarch 21, 2025 | marketbeat.comInvivyd Reports Strong Revenue Growth and Promising DevelopmentsMarch 21, 2025 | tipranks.comInvivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue EstimatesMarch 20, 2025 | zacks.comInvivyd, Inc. Reports 48% Q4 Revenue Growth for PEMGARDA™ and Advances Next-Generation Antibody VYD2311March 20, 2025 | quiverquant.comInvivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business HighlightsMarch 20, 2025 | globenewswire.comInvivyd (IVVD) Projected to Post Earnings on ThursdayMarch 20, 2025 | marketbeat.comAre Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?March 12, 2025 | msn.comInvivyd (NASDAQ:IVVD) Receives Buy Rating from D. Boral CapitalMarch 6, 2025 | marketbeat.comInvivyd, Inc. (NASDAQ:IVVD) Short Interest UpdateMarch 6, 2025 | marketbeat.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1March 5, 2025 | finanznachrichten.deInvivyd announces in vitro neutralization data for PEMGARDAMarch 5, 2025 | markets.businessinsider.comInvivyd, Inc. Reports Positive In Vitro Neutralization Data for PEMGARDA™ Against Dominant SARS-CoV-2 Variant LP.8.1March 5, 2025 | quiverquant.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1March 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVM, ARTV, AVTE, and IVVD Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$2.86 -0.14 (-4.67%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$3.03 +0.17 (+5.91%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Aerovate Therapeutics NASDAQ:AVTE$2.52 +0.01 (+0.40%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$2.49 -0.03 (-1.15%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.CEL-SCI NYSE:CVM$0.21 -0.01 (-4.15%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.21 0.00 (-2.09%) As of 09:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Invivyd NASDAQ:IVVD$0.58 +0.04 (+7.24%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.56 -0.02 (-3.64%) As of 09:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
